Follow The Filings

PACB Pacific Biosciences of California

Pacific Biosciences of California earnings company data as of 10:36 AM ET 11/13

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.13 GAAP -0.12 —
Rev $39.5M $40.6M Beat +2.8%

Insider trades

Open-market buys and sales by PACB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PACB insider trades
  • None no insider bought on the open market
  • $33K sold by 1 insider outside a trading plan
  • $2.1M sold by 1 insider under 10b5-1 plans
  1. Kathy Ordonez Director
    Sale
    $33K 18,595 shares at $1.78 4.6% of stake
    Traded Nov 17 Filed Nov 19
  2. James R. Gibson II See Remarks
    Planned sale
    $2.1M 661,815 shares at $3.11 38% of stake
    Traded Oct 6 Filed Oct 8

Also filed in the last 12 months, not counted as buying or selling: 11 sales to cover taxes, 8 stock grants, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
424B5
8-K 1.01,9.01
SCHEDULE 13G —
SCHEDULE 13G —
10-Q
8-K 2.02,5.02,9.01
SCHEDULE 13G/A —
10-Q
8-K 2.02,2.05,5.02,7.01,9.01
8-K 5.02
8-K 5.02,5.07,9.01
DEFA14A
10-Q
8-K 2.02,9.01
DEF 14A
DEFA14A
SCHEDULE 13G/A —
8-K 5.02,7.01
8-K 5.02,7.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf